ArticleLaryngoscope investigative otolaryngology2025
Biologic Therapy Relieves Otologic Symptoms and Signs in Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease.Frontiers in immunology · 2026Review
- Biologic Therapy Relieves Otologic Symptoms and Signs in Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Multiple biologics are available for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Otologic symptoms are common among these patients, and otitis media (OM) is considered part of the associated eosinophilic multimorbidity. However, few studies describe the effect of biologics on OM. This study aimed to explore whether type 2 anti-inflammatory biologics can also alleviate otologic symptoms and signs. Methods: We retrieved patients who were prescribed biologics for CRSwNP from the electronic patient records (EPRs) of a tertiary referral ear, nose, and throat center. We also included patients from two previous studies on otologic manifestations of NSAID-exacerbated respiratory disease (NERD), who were prescribed biologic medication at a skin and allergy center. Patients who were followed up for less than 12 months were excluded. Demographic information and the response to the biologic therapy were collected from EPRs. Regular appointments were at 0, 4-8, and 12 months, and included a physical examination by ear, nose, and throat (ENT) specialist and two validated patient-reported outcome measures (PROMs): the Sino-Nasal Outcome Test-22 (SNOT-22) and the otology-specific Ear Outcome Survey-16 (EOS-16). Results: All of the 40 patients included had CRSwNP, and 90% had asthma. A total of 17 (42.5%) had clinical otologic signs before starting biologic medication. The main indications for biologic therapy were CRSwNP (70%) and asthma (22.5%). Three patients (7.5%) had both CRSwNP and asthma, but their severe OM symptoms were the main indication for biologic therapy. The SNOT-22 scores were significantly lower at 12 months in all the ear/facial domain questions: ear fullness ( Conclusion: The biologics prescribed for asthma and CRSwNP significantly reduced otologic symptoms and signs. Prospective studies are warranted to explore associated OM as a new target for biologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.